Applying AI to Real-World Data to Improve Pharmaceutical Development
January 18, 2022 | Trends from the Trenches—Xiong Sean Liu is a Director at Novartis where he has been working to make inroads for AI in pharma. In Liu’s view, AI as...
News from the healthcare data industry
January 18, 2022 | Trends from the Trenches—Xiong Sean Liu is a Director at Novartis where he has been working to make inroads for AI in pharma. In Liu’s view, AI as...
January 14, 2022 By Joseph Moss, International Banker We are now comfortably in the era of data, with more and more of it being generated with every passing year. And looking...
Historically, drug researchers have relied on methods such as focus groups, interviews and questionnaires for first-person accounts of patient-reported outcomes, views, symptoms, use of competitive products and other relevant data...
Dive Brief: U.S. digital health startups nabbed a record $29.1 billion in funding in 2021, nearly double the investment volume in the year prior, according to a new report from Rock Health....
VANCOUVER, BC, Jan. 4, 2022 /CNW/ – On the 17th December 2021 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) produced guidance acknowledging and setting out the criteria for the use of Real...
By Tamra Sami PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) has undertaken a massive effort to reform its drug and device regulations, and as it pulls into the homestretch with those reforms,...
31 Dec 2021 NEWS Â Vibha Sharma Executive Summary The UK Medicines and Healthcare products Regulatory Agency has finalized the first part of a series of new guidance documents addressing issues...
The companies will reportedly focus on exploring real-world evidence and conducting clinical trials through G42 Healthcare’s Contract Research Organisation, IROS.By Rachel McArthurDecember 24, 202108:37 AM Credit: iStock AstraZeneca has teamed...
By Mark McCarty The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has unveiled two guidances for the use of real-world evidence (RWE) in regulatory decision-making. The policy seems limited to pharmaceutical clinical...
Real-world data from the PACIFIC-R trial (NCT03798535) evaluating durvalumab (Imfinizi) following chemoradiotherapy in patients with stage III, unresectable non–small cell lung cancer (NSCLC) provide evidence supporting the agent’s efficacy in...